CG
VRTX icon

Cutler Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Cutler Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-400
Closed -$2K – 5299
2022
Q3 		$2K Sell
400
-29,500
-99% -$8.49M ﹤0.01% 4326
2022
Q2 		$2.43M Sell
29,900
-18,900
-39% -$5.06M 0.17% 130
2022
Q1 		$2.25M Buy
48,800
+25,300
+108% +$6M 0.12% 190
2021
Q4 		$1.06M Buy
+23,500
New +$4.57M 0.04% 438
2021
Q2 		– Sell
-1,500
Closed -$11K – 6433
2021
Q1 		$11K Buy
1,500
+400
+36% +$87.9K ﹤0.01% 3751
2020
Q4 		$31K Hold
1,100
– – ﹤0.01% 2346
2020
Q3 		$74K Hold
1,100
– – ﹤0.01% 1518
2020
Q2 		$98K Hold
1,100
– – 0.01% 1324
2020
Q1 		$54K Hold
1,100
– – ﹤0.01% 1681
2019
Q4 		$41K Hold
1,100
– – ﹤0.01% 1763
2019
Q3 		$16K Buy
1,100
+100
+10% +$17.7K ﹤0.01% 2345
2019
Q2 		$21K Sell
1,000
-6,800
-87% -$1.19M ﹤0.01% 2183
2019
Q1 		$4K Sell
7,800
-6,300
-45% -$1.16M ﹤0.01% 3086
2018
Q4 		$82K Sell
14,100
-800
-5% -$139K 0.01% 1164
2018
Q3 		$291K Sell
14,900
-500
-3% -$89K 0.02% 677
2018
Q2 		$235K Sell
15,400
-13,200
-46% -$2.05M 0.02% 716
2018
Q1 		$349K Sell
28,600
-20,100
-41% -$3.28M 0.03% 549
2017
Q4 		$542K Sell
48,700
-39,700
-45% -$5.88M 0.02% 520
2017
Q3 		$1.32M Buy
88,400
+300
+0.3% +$45.2K 0.05% 279
2017
Q2 		$1.07M Sell
88,100
-47,800
-35% -$5.75M 0.04% 395
2017
Q1 		$1.87M Buy
135,900
+35,500
+35% +$3.13M 0.08% 223
2016
Q4 		$252K Buy
100,400
+19,800
+25% +$1.61M 0.01% 1130
2016
Q3 		$204K Buy
80,600
+36,300
+82% +$3.43M 0.01% 1191
2016
Q2 		$180K Sell
44,300
-8,300
-16% -$717K 0.01% 1190
2016
Q1 		$148K Sell
52,600
-5,200
-9% -$470K 0.01% 1239
2015
Q4 		$714K Buy
+57,800
New +$6.98M 0.04% 463

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Cutler Group's VRTX Position: Q4 2022 in Review

Cutler Group sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 200 shares — an estimated $57K sold.

Cutler Group first reported a position in VRTX in Q4 2015 and held it in 24 quarters. The position peaked at $6.76M in Q3 2017. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

  • Cutler Group reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 200 Vertex Pharmaceuticals shares in Q4 2022, an estimated $57K.
  • Cutler Group first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 24 quarters.
  • Cutler Group's Vertex Pharmaceuticals position peaked at $6.76M in Q3 2017.
  • 1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.